WELCOME TO iNANOD
NANO-TECHNOLOGY BASED CANCER DRUG DEVELOPMENT
WHAT WE DO
Current developments in nanomedicine research has inspired iNANOD co-founders to start an entrepreneurial journey utilizing nanotechnology to improve cancer treatment. iNANOD`s research is based on a nanotechnology-based platform, improving the efficacy and reducing side-effects of chemotherapeutic medications by optimizing drug delivery platform. This approach will ensure an optimal targeting and concentration of delivered drug to the diseased tissue. Our mission is to commercialize the research to benefit patients and society.
ABOUT
iNANOD AS is a privately owned start-up company growing through the pull mechanism of innovation from the Oslo Cancer Cluster Incubator. iNANOD utilizes nano-biotechnology to establish a platform to improve drug delivery, especially within oncology. It has the ambition to deliver the active pharma ingredient in a targeted and accelerated way while generating immunotherapy. Therefore envisioning to kill cancer cells target-specifically by combined double actions of chemo and immunotherapy in solid malignant tumours.
Ready to take the next step? You can become a contributor to our research program, and investment that will support the strategy to improve cancer therapy by utilizing the potential of nanotechnology in medicine. In case you are an investor or a philanthropist looking to support iNANOD, please contact us.
THE PEOPLE
BOARD MEMBERS
Åge Nærdal
Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.
Chairman
Hilde Nilsen
Co-founder
Professor in Department of Clinical Molecular Biology, Head (Epigenetics), Akershus University Hospital.
Nalinava Sengupta
Co-founder
After 15 years of academic research in chemistry, turned entrepreneur for a mission.
Jørn Lein-Mathisen
Business angel. Business development and entrepreneurial experiences internationally over 28 years.
SUPPORTED BY...
MEMBER OF
